(April 27, 2016, 2:22 PM EDT) -- WASHINGTON, D.C. — Amgen Inc. and Amgen Manufacturing Limited (Amgen, collectively) on March 21 asked the U.S. Supreme Court to review an appellate court’s conclusion that the word "shall" in a statute "does not mean 'must'" and that a sponsor's sole remedy in the face of applicant noncompliance is to file a declaratory judgment action or a patent infringement action (Amgen, Inc. and Amgen Manufacturing, Ltd. v. Sandoz, Inc., No. 15-1195, U.S. Sup.)....